RT Journal Article
SR Electronic
T1 JAK signaling was involved in the pathogenesis of Polymyalgia Rheumatica
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.10.22272242
DO 10.1101/2022.03.10.22272242
A1 Yang, Fan
A1 Ma, Xinlei
A1 Xu, Bei
A1 Sun, Yiduo
A1 Jiang, Mengdi
A1 Ren, Chunyun
A1 Sun, Chuanying
A1 Liang, Junyu
A1 Cao, Heng
A1 Xu, Danyi
A1 Yue, Lihuan
A1 Xu, Liqin
A1 Lin, Jin
A1 Chen, Weiqian
YR 2022
UL http://medrxiv.org/content/early/2022/03/13/2022.03.10.22272242.abstract
AB Objectives Polymyalgia Rheumatica (PMR) is a common inflammatory disease in elderly persons whose pathogenesis is unclear. We aimed to explore the pathogenetic features of PMR and find a new therapeutic strategy.Methods We included 11 patients with PMR and 20 age-matched and sex-matched healthy controls (HC) in this study. The disease features were described. The gene expression profiles were analyzed in peripheral blood mononuclear cells (PBMCs) by RNA sequencing and were confirmed by RT-PCR. We also tested gene expression profiles in five patients with PMR after tofacitinib therapy.Results Patients with PMR experienced pain with high disease activity scores. The gene expression of PBMCs in patients with PMR differed from that in HC by RNA sequencing. GO and KEGG analysis demonstrated that inflammatory response and cytokine-cytokine receptor interaction were the most remarkable pathways. There were markedly expanded IL6R, IL1B, IL1R1, JAK2, TLR2, TLR4, TLR8, CCR1, CR1, S100A8, S100A12, and IL17RA expressions. Those genes may trigger the JAK signaling. Furthermore, tofacitinib, a pan JAK inhibitor, effectively treated five patients with PMR, leading to clinical remission and a significant decrease in inflammatory genes.Conclusions Many inflammatory genes associated with JAK signaling were increased in patients with PMR, suggesting an important role of JAK signaling in PMR disease development. JAK inhibitors may effectively treat PMR.Key messagesPatients with PMR had significant inflammatory genes expression. JAK signaling may be highly activated.Tofacitinib may treat PMR with clinical remission and a significant decrease in inflammatory genes.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000038253Clinical Protocols http://www.chictr.org.cn/ Funding StatementThis work was supported in part by grants from Natural Science Foundation of China (82171768).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Medical Ethical Committee of the First Affiliated Hospital, Zhejiang University (IIT20200070C-R1).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.